Term
|
Definition
| s chemical substance used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being |
|
|
Term
|
Definition
| a biological molecule such as a protein that is known to or is predicted to bind with high affinity to a drug. |
|
|
Term
|
Definition
no molecules can be identified that modulate a target of interest OR
-a potent and selective inhibitor is found against the target, but it has no effect on the disease for which it was intended |
|
|
Term
|
Definition
| the specific biochemical interaction through which a drug substance produces its pharmacological effect |
|
|
Term
|
Definition
| a sequence of DNA that codes information for protein synthesis that is transcribed to messenger RNA |
|
|
Term
|
Definition
| a segment of the DNA molecule which is capable of increasing or decreasing the transcription of specific genes |
|
|
Term
| SNPs - single nucleotide polymorphism (3) |
|
Definition
| a DNA sequence variation occurring when a single nucleotide differ between individuals |
|
|
Term
|
Definition
| a gene that causes normal cells to become cancerous either because the gene is mutated or because the gene is (over)-expressed at the wrong time in developement |
|
|
Term
| chromosomal translocation (4) |
|
Definition
| an abnormality caused by rearrangement of parts between chromosomes. a gene fusion may be created when the translocation joins two otherwise separated genes, the occurrence of which is common in cancer |
|
|
Term
|
Definition
| an enzyme that catalyzes the transfer of a phosphate group from ATP to an accepter, usually another kinase |
|
|
Term
|
Definition
| currently over 500 protein/lipid kinases that exist within the human genome |
|
|
Term
|
Definition
| the N-terminal regulatory domain and the highly conserved C-terminal catalytic lobe common to all kinases |
|
|
Term
| Type I Kinase inhibitor (5) |
|
Definition
| binds to the ATP Binding site of the enzyme in its active form |
|
|
Term
| Type II Kinase inhibitor (5) |
|
Definition
| binds to the inactive form of the enzyme |
|
|
Term
|
Definition
| a drug's actions, usually unanticipated, other than those for which the agent was specifically developed. May include adverse side effects, but often used to denote beneficial effects |
|
|
Term
|
Definition
| protein molecules that manipulate other molecules (substrates). uses active site to bind target molecules and transform them into products through a series of steps (enzymatic mechanism) |
|
|
Term
|
Definition
| the molecule upon which the enzyme acts in the chemical transformation of product formation |
|
|
Term
|
Definition
| the reaction rate of a chemical reaction that is catalyzed by an enzyme |
|
|
Term
|
Definition
| the maximum catalytic rate achieved at saturation |
|
|
Term
|
Definition
| the concentration of substrate that results in half the Vmax |
|
|
Term
|
Definition
| fraction of incident radiation (photon) absorbed by a molecule over a range of frequencies |
|
|
Term
|
Definition
| the emission of light by a substance that has absorbed light or other energy |
|
|
Term
|
Definition
| the difference in wavelength between the absorption and emission peaks |
|
|
Term
| Fluorescence Resonance Energy Transfer (FRET) |
|
Definition
| the fluorescence of an acceptor molecule is measured upon excitation by the fluorescence of a donor molecule |
|
|
Term
|
Definition
| a molecule with a long-lived fluorescence signal (1-2 milliseconds) |
|
|
Term
|
Definition
| a molecule with an absorption excitation spectrum that coincides with the emission spectrum of the TRF Donot |
|
|
